Home › Esophageal Adenocarcinoma › California › Irvine
Esophageal Adenocarcinoma clinical trials in Irvine, CA
4 studies for Esophageal Adenocarcinoma are looking for participants at sites in and around Irvine (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
RecruitingPhase 2/3
- Kaiser Permanente-Irvine, Irvine
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
RecruitingPhase 3
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RecruitingPhase 1
- City of Hope at Irvine Lennar, Irvine
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
RecruitingPhase 3
- Research Site, Irvine
Esophageal Adenocarcinoma trials in other cities
- New York City, NY18 studies
- Boston, MA13 studies
- Houston, TX12 studies
- Nashville, TN11 studies
- Arlington, VA11 studies
- Durham, NC10 studies
- Jacksonville, FL9 studies
- St. Louis, MO9 studies
- Rochester, MN9 studies
- Baldwin Park, CA9 studies
- Queens, NY9 studies
- Los Angeles, CA9 studies
Other studies in Irvine
- Non-Small Cell Lung Cancer25 studies
- Breast Cancer23 studies
- Cancer (all types)17 studies
- Metastatic Cancer16 studies
- Lung Cancer15 studies
- Multiple Myeloma14 studies
- Prostate Cancer14 studies
- Ovarian Cancer12 studies
- Head and Neck Squamous Cell Carcinoma11 studies
- Bladder Cancer11 studies
- Alzheimer's Disease11 studies
- Colorectal Cancer10 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.